Bristol Interstitial Lung Disease Service, Southmead Hospital, North Bristol NHS Trust, Bristol, UK
Bristol Interstitial Lung Disease Service, Southmead Hospital, North Bristol NHS Trust, Bristol, UK.
Eur Respir Rev. 2020 May 15;29(156). doi: 10.1183/16000617.0167-2019. Print 2020 Jun 30.
Hypersensitivity pneumonitis (HP) is an immunologically mediated lung disease resulting from exposure to inhaled environmental antigens. Prognosis is variable, with a subset of patients developing progressive fibrosis leading to respiratory failure and death. Therefore, there is an urgent need to identify factors which predict prognosis and survival in patients with HP. We undertook a narrative review of existing evidence to identify prognostic factors in patients with chronic HP. Patient demographics, smoking history, extent of antigen exposure and comorbidities all have reported associations with disease outcome, and physiological, radiological and laboratory markers have been shown to predict overall survival. While no single marker has been demonstrated to accurately and reliably predict prognosis, older age, more severe impairment of pulmonary function at baseline and established fibrosis on either biopsy or high-resolution computed tomography are consistently associated with worse survival. The vast majority of existing studies are retrospective, and this review identifies a need for prospective longitudinal studies with serial assessment of respiratory health to ascertain factors associated with nonfatal deterioration. Future developments, including the development of HP-specific composite scores may help further improve our ability to predict outcomes for individual patients.
过敏性肺炎(HP)是一种由吸入环境抗原引起的免疫介导性肺部疾病。预后各不相同,一部分患者会发展为进行性纤维化,导致呼吸衰竭和死亡。因此,迫切需要确定预测 HP 患者预后和生存的因素。我们对现有证据进行了叙述性综述,以确定慢性 HP 患者的预后因素。患者的人口统计学特征、吸烟史、抗原暴露程度和合并症都与疾病结局有关,生理、放射学和实验室标志物已被证明可以预测总生存率。虽然没有单一的标志物被证明能够准确可靠地预测预后,但年龄较大、基线时肺功能更严重受损以及活检或高分辨率计算机断层扫描上已确立的纤维化与更差的生存率一致相关。绝大多数现有研究都是回顾性的,本综述确定了需要进行前瞻性纵向研究,对呼吸健康进行连续评估,以确定与非致命性恶化相关的因素。未来的发展,包括 HP 特异性综合评分的开发,可能有助于进一步提高我们预测个别患者结局的能力。